News

Possible connection between exposure to endocrine disruptors and COVID-19 severity
November 23, 2020
> News & Press Releases > Publications

NEW ARTICLES : New press articles have been posted on the link between ED’s exposure and COVID-19 severity Inserm press article “Rôle possible de l’exposition aux perturbateurs endocriniens dans la sévérité de la Covid-19” Pubmed article “New research examines suspected links between EDCs exposure and COVID-19” Inserm article (FR) Pubmed article (EN)

PUBLICATION IN TOX. AND APPLIED PHARMACO. BY KARINE AUDOUZE
August 27, 2020
> All news > Dissemination > Publications

Biological systems are disturbed by several factors that are defined by the exposome. Environmental substances, including endocrine disruptors (EDs), represent the chemical exposome. These stressors may alter biological systems, that could lead to toxic health effects. Even if scientific evidence provide links between diverse environmental substances and disorders, innovative approaches, including alternative methods to animal testing, are still needed to address the complexity of the chemical mechanisms of action.

OBERON press release
14 April 2019
> News & Press Releases

Coordinated by Inserm, the European project OBERON aims to develop panels of tests that will – eventually – make it possible to determine with more accuracy and certitude how compounds suspected of being endocrine disruptors might induce metabolic disorders and, ultimately, to identify these compounds.

OBERON project – Kick-off
8 February 2019
> Dissemination

The OBERON project has started on 1st January 2019.
OBERON Kick-Off Meeting took place on the 8st of February 2019 in Brussels, Belgium. This meeting gathered all 11 partners from 6 countries for presenting the planned work program.

EURION Cluster Launch Event
1st January 2019
> News & Press Releases

Joint Launch Event of Projects from the Call ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals’ The current testing tools, including regulatory in vivo tests and novel in vitro assays, do not appropriately identify effects related to certain less studied endocrine-mediated pathways or health outcomes, in which endocrine disruptors may be implicated. The focus of proposals should Read the full article…

© OBERON 2019, Website Created by FMOSys